|Bid||0.0000 x 800|
|Ask||0.0000 x 2200|
|Day's Range||0.5700 - 0.6163|
|52 Week Range||0.4840 - 3.6400|
|Beta (3Y Monthly)||1.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.77|
CULVER CITY, Calif.-- -- Total revenue in Q1 was $23.7 million, up 7% from Q1 2018 SaaS revenue of $17.8 million in Q1, up 10% from Q1 2018 and 3% sequentially Signed Substantial Three-year Eviti Contract with Multi-state Healthcare Payer Sequencing and Molecular Analysis, 820 total tests ordered in Q1, including 428 GPS Cancer® and 392 Liquid GPS SM Tests NantHealth, Inc. , a next-generation, evidence-based, ...
NantHealth Inc NASDAQ/NGS:NHView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for NH with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding NH are favorable, with net inflows of $540 million. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
NantHealth, Inc. , a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2019 first quarter on Thursday, May 9, 2019, after market close.
NantHealth, Inc. , a next-generation, evidence-based, personalized healthcare company, will present on Connected Care VitalsConX technology at the American Nursing Informatics Association Annual Conference taking place April 12-13, 2019 at the Rio All Suite Hotel & Casino in Las Vegas, NV in booth #213.
CULVER CITY, Calif.-- -- Total Revenue in Q4 was $22.9 Million SaaS revenue of $17.3 million in Q4, up 9% from Q3 Enhanced efficiencies continued to drive significantly lower operating expenses in both Q4 and full year of 2018 For 2018, substantially improved adjusted Non-GAAP bottom line results Sequencing and Molecular Analysis, 1,021 total tests ordered in Q4, including 539 GPS Cancer® and 482 Liquid ...
NEW YORK, NY / ACCESSWIRE / March 28, 2019 / NantHealth, Inc. (NASDAQ: NH ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 28, 2019 at 4:30 PM Eastern ...
NantHealth, Inc. , a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2018 fourth quarter on Thursday, March 28, 2019, after market close.
NantHealth, Inc. , announced an agreement with Northwest Fire Fighters Benefits Trust , one of the largest firefighter healthcare trusts in the U.S., to ensure all NWFFT covered plan members with access to NantHealth’s GPS Cancer and Liquid GPS molecular profiling tests.
CORAL GABLES, FL / ACCESSWIRE / March 11, 2019 / The success of the tech stock market is directly correlated to the operating assumption that tech companies are prepared to meet the rising challenges presently facing society. As we've seen in the first few months of 2019, the tech sector is booming with the excitement surrounding companies working on advanced technologies meant to take humanity into the future. ParcelPal Technology Inc (PTNYF) (PKG), Plug Power Inc (PLUG), Leap Therapeutics Inc (LPTX) and NantHealth Inc (NH) represent 4 tech stocks on the rise on Monday.
CORAL GABLES, FL / ACCESSWIRE / March 8, 2019 / When it comes to discussing healthcare stock market, it goes without saying that the success of the market is directly connected to if companies in the healthcare industry are doing their part to take care of consumers. It is the responsibility of healthcare companies to work to develop innovative treatments and care options for consumers, especially at a time where new diseases are discovered on a frequent basis. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Tonix Pharmaceuticals Holding Corp (TNXP), Steller Biotechnologies Inc (SBOT), NantHealth Inc (NH) are 4 healthcare companies stepping up their game on Friday.
Findings to be presented at the 2019 American Society of Clinical Oncology’s Genitourinary Cancers Symposium
NantHealth, Inc. (NH), a leader in connected care solutions, will unveil a series of new initiatives designed to improve patient outcomes and provider satisfaction at the 2019 Healthcare Information and Management Systems Society (HIMSS) Annual Conference and Exhibition taking place this week in Orlando. NantHealth’s main booth location will be #4944. The company will also be featured in the HIMSS Interoperability Showcase™ and the Intelligent Health Pavilion™.
@baxter_intl and @NantHealth advance DigitalHealth technology for medical devices in the hospital ICU #CriticalCare #HIMSS19
If you own shares in NantHealth, Inc. (NASDAQ:NH) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of Read More...
NantCell, a cancer treatment company founded by biotech entrepreneur Dr. Patrick Soon-Shiong, has received an additional $30 million investment from drug maker Celgene Corp.
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.